https://www.live-feeds.com/feed/abbvie-s-cerevel-buyout-delivers-as-fda-gives-go-ahead-to-1st-in-class-juvmo-in-parkinson-s-diseaseContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/abbvie-s-cerevel-buyout-delivers-as-fda-gives-go-ahead-to-1st-in-class-juvmo-in-parkinson-s-diseasehttps://www.live-feeds.com/feed/abbvie-s-cerevel-buyout-delivers-as-fda-gives-go-ahead-to-1st-in-class-juvmo-in-parkinson-s-disease#u101181Mon, 05 Oct 2026 03:31:38 +0000The US FDA approved Juvmo (tavapadon), a once-daily oral medication for adults with Parkinson's disease. Juvmo is the first and only selective D1/D5 receptor agonist in its class. The drug showed significant improvements in motor symptoms and longer periods of symptom control during the Phase 3 TEMPO program. This approval represents the first product delivered from AbbVie's 8.7 billion dollar acquisition of Cerevel, which took place two years ago. Despite the approval, AbbVie management expects a slow start for the medication's market entry.Why it mattersThe approval validates